A Study of AG-636 in the Treatment of Subjects With Advanced Lymphoma
Status:
Terminated
Trial end date:
2020-06-17
Target enrollment:
Participant gender:
Summary
This study will evaluate the safety, pharmacokinetics, pharmacodynamics, and clinical
activity of AG-636, an oral Dihydroorotate Dehydrogenase (DHODH) inhibitor, in subjects with
advanced lymphoma.